This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stenmark, K. R. Articles by Balasubramaniam, V. Search for Related Content PubMed PubMed Citation Articles by Stenmark, K. R. Articles by Balasubramaniam, V. Related Collections Angiogenesis Animal models of human disease Other Vascular biology

(Circulation. 2005;112:2383-2385.)
© 2005 American Heart Association, Inc.

Editorial

Angiogenic Therapy for Bronchopulmonary Dysplasia

Rationale and Promise

Kurt R. Stenmark, MD; Vivek Balasubramaniam, MD

From the Divisions of Critical Care and Pulmonary Medicine (K.R.S.) and the Department of Pediatrics (V.B.), University of Colorado at Denver and Health Sciences Center, Denver, Colo.

Correspondence to Kurt R. Stenmark, MD, University of Colorado at Denver and Health Sciences Center, 4200 E 9th Ave, Campus Box B131, Denver, CO 80262. E-mail Kurt.Stenmark@UCHSC.edu

Key Words: Editorials • angiogenesis • gene therapy • pediatrics • morphogenesis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Bronchopulmonary dysplasia (BPD) is one of the most common and significant medical complications associated with preterm birth, affecting 5000 to 10 000 babies annually. It was originally defined as a disorder occurring in infants who were ventilated for neonatal respiratory distress with the primary lung features being mucosal metaplasia of the airways, emphysema, widespread interstitial fibrosis, and remodeling of the small pulmonary arteries.¹ Improvements in neonatal care, including antenatal steroids, surfactant therapy, better ventilator strategies, and improved nutritional support, although not reducing the incidence of the disease (the overall numbers of patients with BPD has increased), have led to the development of what is now called "the new BPD." This so-called new BPD is characterized histopathologically primarily by an impairment of alveolar formation, which often leads to long-term global reductions in alveolar number and gas exchange surface area.^2–4 This impairment of alveolar and vascular development is believed to contribute increased morbidity including the development of late cardiopulmonary disease, exercise intolerance, increased risk of asthma, pulmonary hypertension, and the development of chronic obstructive pulmonary disease in these infants as they grow into adulthood.⁴ Thus, therapies aimed at promoting lung alveolar and vascular growth in these infants may be highly beneficial in the prevention of these sequelae of premature birth.

Article p 2477

BPD is a multifactorial disease resulting from the impact of injury (including oxygen toxicity, barotrauma, volutrauma, and infection) on the immature lung. Infants most susceptible to the development of BPD (<750 to 1000 g and 28 weeks’ gestation) are . . . [Full Text of this Article]

This article has been cited by other articles:

				T. E. Tipple, S. E. Welty, L. D. Nelin, J. M. Hansen, and L. K. Rogers Alterations of the Thioredoxin System by Hyperoxia: Implications for Alveolar Development Am. J. Respir. Cell Mol. Biol., November 1, 2009; 41(5): 612 - 619. [Abstract] [Full Text] [PDF]

				J. Pang, R. Hoefen, G. S. Pryhuber, J. Wang, G. Yin, R. J. White, X. Xu, M. R. O'Dell, A. Mohan, H. Michaloski, et al. G-Protein-Coupled Receptor Kinase Interacting Protein-1 Is Required for Pulmonary Vascular Development Circulation, March 24, 2009; 119(11): 1524 - 1532. [Abstract] [Full Text] [PDF]